Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 321

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 321
---
 registered direct offering. In addition, in a concurrent private placement, we issued to the investors unregistered
warrants to purchase 1,817,017 shares of common. The combined purchase price for one share of common stock and one warrant was $1.175,
resulting in gross proceeds of approximately $2.135 million.

66

In
August 2024, we completed a registered direct offering, pursuant to which we sold and issued to certain investors, 1,643,837 shares of
common stock. In addition, in a concurrent private placement, we issued to the investors unregistered warrants to purchase 1,643,837
shares of common stock. The combined purchase price for one share of common stock and one warrant was $1.825, resulting in gross proceeds
of approximately $3.0 million.

In
June 2022, we entered into an At The Market Offering Agreement (the “ATM Agreement”) which was amended on September 1, 2022
with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which we may offer and sell, from time to
time through Wainwright, shares of our common stock, par value $0.01 per share, for aggregate gross proceeds of up to $3.7 million. The
issuance and sale of common stock by us under the ATM Agreement is being made pursuant to our effective “shelf” registration
statement on Form S-3 filed with the SEC on September 1, 2022 and declared effective on September 9, 2022. In 2024, we sold 152,000 shares
of our common stock for aggregate gross proceeds of approximately $0.4 million. On August 6, 2024, we filed a prospectus supplement to
reduce the amount of shares registered under the prospectus for the ATM to $0.00 and to suspend the ATM program, but the ATM Agreement
remains in full force and effect.

In
February 2025, we entered into a SEPA with Yorkville pursuant to which we have the right, but not
the obligation, to sell up to $20.0 million of our common stock during a 36 month period, subject to the restrictions and satisfaction
of the conditions in the SEPA. Upon execution of the SEPA, we issued to Yorkville 305,960 commitment shares. No shares of common
stock have been sold under the SEPA.

We